BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 11, 2016
View Archived Issues
BioMed X and J&J to develop biofilm inhibitors for oral health applications
Read More
ChemoCentryx provides update on CCX-168
Read More
Verastem initiates phase I trial of defactinib, pembrolizumab and gemcitabine in pancreatic cancer
Read More
SolaranRx enters into CRADA with NCI to advance metastatic melanoma theranostic
Read More
Peregrine and NCCN establish research collaboration to advance development of bavituximab
Read More
C4 Therapeutics launches from Dana-Farber, enters collaboration with Roche
Read More
Principia advances two programs in clinic
Read More
ViiV Healthcare and Janssen to collaborate to develop rilpivirine and cabotegravir regimen
Read More
Gilead reports topline data from phase III studies of tenofovir alafenamide in chronic HBV
Read More
uniQure reports on low-dose cohort in phase I/II hemophilia B trial of AMT-060
Read More
X-Chem forms discovery collaboration with Sanofi
Read More
Checkpoint Therapeutics to obtain rights to Teva's oral PARP inhibitor
Read More
Aridis reports promising phase I data on Aerucin
Read More
Gruenenthal discloses CRAC blockers
Read More
NKTT-120 reduces iNKT cells in patients with sickle cell disease
Read More
Bayer Schering Pharma reports BRD4 inhibitors
Read More
The University of Montana presents SLC7A11 inhibitors
Read More
Johnson & Johnson Innovation discloses a plethora of new collaborations
Read More
XBiotech reports data from phase III European trial of Xilonix
Read More
AbbVie begins phase III program evaluating ABT-494 for rheumatoid arthritis
Read More
Gruenenthal and Akashi Therapeutics form joint drug development program for HT-100
Read More
PSMA-targeted ACCURIN shows promise for mCRPC
Read More
ImaginAb presents data on PSMA imaging agent for diagnosis of prostate cancer
Read More
PTC Therapeutics completes rolling NDA for Translarna, submits phase III data to EMA
Read More
FDA grants orphan drug designation to components of Immune Design's CMB-305
Read More